These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 7672923)

  • 1. [Comment on the information by the Federal Drug and Medical Products Institute on "calcium channel blockers of the 1,4-dihydropyridine class"].
    Trenkwalder P
    Internist (Berl); 1995 Jul; 36(7):730-1. PubMed ID: 7672923
    [No Abstract]   [Full Text] [Related]  

  • 2. [New calcium antagonist. Therapy of hypertension becomes more tolerable].
    MMW Fortschr Med; 2001 Oct; 143(40):56-7. PubMed ID: 11692852
    [No Abstract]   [Full Text] [Related]  

  • 3. [Drug information about lercanidipine. A new dihydropyridine calcium antagonist for the treatment of arterial hypertension].
    Christensen KL
    Ugeskr Laeger; 2005 Jan; 167(2):153-5. PubMed ID: 15697124
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardiovascular advantages of a third generation calcium antagonist. Symposium on lacidipine. Foreword.
    Zanchetti A
    Drugs; 1999; 57 Suppl 1():2 p preceding 1. PubMed ID: 10529077
    [No Abstract]   [Full Text] [Related]  

  • 5. Dihydropyridine calcium channel blockers and peripheral side effects.
    Sirker A; Missouris CG; MacGregor GA
    J Hum Hypertens; 2001 Oct; 15(10):745-6. PubMed ID: 11607807
    [No Abstract]   [Full Text] [Related]  

  • 6. [Hypertension in type 2 diabetic patients. Calcium antagonist supports the left heart].
    MMW Fortschr Med; 2001 Jun; 143(25):58. PubMed ID: 11469003
    [No Abstract]   [Full Text] [Related]  

  • 7. Dihydropyridines, felodipine, and PHARMAC.
    Mann S
    N Z Med J; 2005 Jul; 118(1218):U1569. PubMed ID: 16027743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Also for problem cases; successful first line therapy].
    MMW Fortschr Med; 2005 Feb; 147(5):47. PubMed ID: 15766030
    [No Abstract]   [Full Text] [Related]  

  • 9. [Calcium channel blockers in the treatment of hypertension and ischemic coronary disease. Conflicts in their evaluation].
    Mayer O
    Cas Lek Cesk; 1998 Apr; 137(7):216-9. PubMed ID: 9650344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Manidipine hydrochloride-induced chyloperitoneum in a patient with systemic lupus erythematosus.
    Tanabe M; Iwata H; Kinoshita M; Sumiya M; Saima S
    Clin Nephrol; 1999 Mar; 51(3):195-6. PubMed ID: 10099897
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of calcium antagonists on sympathetic activity.
    Grossman E; Messerli FH
    Eur Heart J; 1998 Jun; 19 Suppl F():F27-31. PubMed ID: 9651732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Do the newer calcium channel blockers replace the older ones?].
    Jounela A
    Duodecim; 1993; 109(20):1815-20. PubMed ID: 7737004
    [No Abstract]   [Full Text] [Related]  

  • 13. Dihydropyridine calcium-channel blockers for the treatment of hypertensive diabetic patients.
    Staessen JA; Birkenhäger WH; Fagard RH
    Eur Heart J; 2000 Jan; 21(1):2-7. PubMed ID: 10610733
    [No Abstract]   [Full Text] [Related]  

  • 14. [Dihydropyridine: what is the status today?].
    Rumboldt Z
    Lijec Vjesn; 1996; 118(1-2):44-5. PubMed ID: 8759422
    [No Abstract]   [Full Text] [Related]  

  • 15. [Calcium channel blockers. Review and attempt at classification].
    van Zwieten PA; Timmermans PB
    Rev Esp Cardiol; 1984; 37(5):322-9. PubMed ID: 6387828
    [No Abstract]   [Full Text] [Related]  

  • 16. Some similarities and differences between verapamil and the dihydropyridines.
    Antonios TF; MacGregor GA
    J Hypertens Suppl; 1998 Jan; 16(1):S31-4. PubMed ID: 9534094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dihydropyridines for treatment of arterial hypertension].
    Bareza N; Gasser S; Toferer E; Scheer E; Pruthi D; Gasser R
    Pharm Unserer Zeit; 2005; 34(5):388-91. PubMed ID: 16180361
    [No Abstract]   [Full Text] [Related]  

  • 18. Calcium antagonists "some agents lower blood pressure and still put the heart at risk"?
    Leenen FH
    Clin Exp Hypertens; 1999; 21(5-6):823-34. PubMed ID: 10423105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short acting dihydropyridine (vasodilating) calcium channel blockers for hypertension: is there a risk?
    Beevers DG; Sleight P
    BMJ; 1996 May; 312(7039):1143-5. PubMed ID: 8620133
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical advantages of lipophilic dihydropyridines.
    Mancia G; Omboni S; Zanchetti A
    Blood Press Suppl; 1998; 2():23-6. PubMed ID: 9850439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.